Efficacy and Safety of Antimicrobial Durations Treatment of Infections Associated With Osteosynthesis Material

NCT ID: NCT05294796

Last Updated: 2024-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

364 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-09

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infections associated with osteosynthesis material are among the most feared and challenging complications of trauma surgery and can lead to total function loss or limb amputation when complete recovery is to be expected without infection.

This is a clinical trial with the purpose of evaluate the optimal duration of antibiotic therapy in Infections Associated With Osteosynthesis Material Implanted when implant is retained.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Orthopedic implants for fracture fixation or osteosynthesis material are used for internal fixation of fractures, allowing their stability and consolidation.

Infection associated with osteosynthesis material is one of the most feared and challenging complications of trauma surgery and can lead to total loss of function or amputation of the limb, when complete recovery is to be expected without infection. Furthermore, they involve excessive consumption of antimicrobials, with inadequate prescriptions and prolonged durations that favour superinfections by multidrug-resistant microorganisms, in addition to the drug-related toxicities, especially diarrhea due to Clostridium difficile. Most studies and recommendations on the management of orthopedic implant-associated infections have focused on prosthetic joint infections, and while they share similarities with Infections Associated With Osteosynthesis Material Implanted, there are major differences in terms of risk factors, diagnosis, treatment, and prevention. While the extrapolation of knowledge from prosthetic joint infections to the field of Infections Associated With Osteosynthesis Material Implanted has helped orthopedic surgeons and internists/infectologists in their management, there are large gaps and unanswered questions that represent a new challenge for research in this field. One of these challenges, and focusing on the field of infection treatment, is the search for the best surgical procedure according to the age of the implant and fracture healing, to determine the duration of antibiotic treatment and whether it should be maintained until fracture healing, and which is the most appropriate treatment in each of the scenarios.

The identification of conditions in which the duration of the antimicrobial treatment can be shortened, and in case of prolonged treatments, which antimicrobial has the best safety profile and less impact on the induction of bacterial resistances is of special interest, due to the frequent appearance of toxicities and the increase of bacterial resistances and superinfections by multidrug-resistant bacteria.

If the hypothesis of non-inferiority of short vs. long antibiotic treatments is demonstrated, and the efficacy of antibiotics with less ecological impact in long treatments, the impact on reduction of bacterial resistance, toxicity and health costs will be observed. The project also aims to promote quality and multidisciplinary care, homogenising clinical practice in the management of Infections Associated With Osteosynthesis Material Implanted based on scientific knowledge. Early and personalised patient care with Infections Associated With Osteosynthesis Material Implanted allows for faster recovery, both clinically and functionally, enabling earlier mobility recovery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Pragmatic, multicenter, non-inferiority, open labelled, randomized trial comparing different durations of antibiotherapy in osteosynthesis material infections after long bone fractures treated with debridement and material retention (see design algorithm and inclusion criteria). The CONSORT extension for pragmatic designs will be used.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Short course of antibiotherapy

Patients enrolled in this arm, will receive 8 weeks of antibiotherapy in case of early infection (\< 2 week), and 12 weeks of antibiotherapy in case of delayed infection (2-10 weeks)

Group Type ACTIVE_COMPARATOR

Short course of antibiotherapy

Intervention Type COMBINATION_PRODUCT

Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Long course of antibiotherapy

Patients enrolled in this arm, will receive 12 weeks of antibiotherapy in case of early infection (\< 2 week), and until fracture healing of antibiotherapy in case of delayed infection

Group Type ACTIVE_COMPARATOR

Long course of antibiotherapy

Intervention Type COMBINATION_PRODUCT

Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Short course of antibiotherapy

Short duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Intervention Type COMBINATION_PRODUCT

Long course of antibiotherapy

Long duration of authorized antibiotic therapy according to its data sheet in infections associated with osteosynthesis material

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 14 years.
* Stable fracture, even if unconsolidated.
* Controlled infection (absence of signs or symptoms of sepsis).
* Early or delayed infection.
* Availability of antibiotics active against the isolated microorganism.
* Absence of bone exposure. Patients who initially had bone exposure but during the debridement surgery bone coverage was performed by any method (skin approximation, grafting, vacuum therapy) can be included in the criteria.
* Signed written informed consent.
* If there is a possibility of pregnancy (in women of childbearing potential) or paternity, agree to use a highly effective method of birth control recommended by the Clinical Trial Facilitation Group (CTFG) during the treatment phase of the trial

Exclusion Criteria

* Late infections
* Infections of osteosynthesis material in non-long bones.
* Infections of revision osteosynthesis material or occurring after previous surgeries.
* Patients who are not expected to be followed up for at least 1 year after completion of antibiotic treatment.
* Pregnant or lactating women.
* Patients in whom there may be drug interactions or contraindications described in the technical data sheets of the investigational drugs used in this trial.
* Infections due to mycobacteria, fungi and parasites (since they are infections that are treated with drugs and for different durations).
* Patients in whom all the material is replaced during the debridement at the same surgical time (since these patients require antibiotic treatment for less than 8 weeks in all cases).
* Infections of external fixators.
Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

María Dolores del Toro López

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Virgen Macarena

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Son Espases

Palma, Balearic Islands, Spain

Site Status RECRUITING

Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, Spain

Site Status RECRUITING

Hospital Universitario Parc Taulí

Sabadell, Barcelona, Spain

Site Status RECRUITING

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Site Status RECRUITING

Hospital Universitario Jerez de la Frontera

Jerez de la Frontera, Cádiz, Spain

Site Status RECRUITING

Hospital San Pedro

Logroño, La Rioja, Spain

Site Status RECRUITING

Hospital Universitario El Bierzo

Ponferrada, León, Spain

Site Status RECRUITING

Hospital Universitario Príncipe de Asturias

Alcalá de Henares, Madrid, Spain

Site Status RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca

El Palmar, Murcia, Spain

Site Status RECRUITING

Hospital Universitario Virgen del Rocío

Seville, Seville, Spain

Site Status RECRUITING

Hospital Universitario de Cruces

Barakaldo, Vizcaya, Spain

Site Status RECRUITING

Hospital del Mar

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Clinic de Barcelona

Barcelona, , Spain

Site Status RECRUITING

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitari de Bellvitge

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Puerto Real

Cadiz, , Spain

Site Status RECRUITING

Hospital Universitario Virgen de las Nieves

Granada, , Spain

Site Status RECRUITING

Hospital Universitario Lucus Augusti

Lugo, , Spain

Site Status RECRUITING

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario Fundación Jiménez Díaz

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario La Paz

Madrid, , Spain

Site Status TERMINATED

Hospital Regional Universitario de Málaga

Málaga, , Spain

Site Status RECRUITING

Hospital Universitario Virgen de la Victoria

Málaga, , Spain

Site Status RECRUITING

Hospital Universitario Costa del Sol

Málaga, , Spain

Site Status RECRUITING

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status RECRUITING

Hospital Universitario Virgen de Valme

Seville, , Spain

Site Status RECRUITING

Hospital Clínico Universitario Lozano Blesa

Zaragoza, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clara Rosso Fernández

Role: CONTACT

955012144

Irene Borreguero Borreguero

Role: CONTACT

955007609

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Helem Haydeen Vilchez Rueda

Role: primary

Esteban Alberto Reynaga Sosa

Role: primary

Eva Van den Eynde Otero

Role: primary

Marta Fernández Sampedro

Role: primary

Virginia Corbacho Sánchez

Role: primary

José Ramon Blanco Ramos

Role: primary

Alberto Bahamonde Carrasco

Role: primary

José María Barbero Allende

Role: primary

Javier Martínez Ros

Role: primary

José Manuel Lomas Cabezas

Role: primary

Laura Guio Carrión

Role: primary

Luisa Sorlí Redó

Role: primary

María Dolores Rodríguez Pardo

Role: primary

Laura Morata Ruiz

Role: primary

Natividad de Benito Hernández

Role: primary

Oscar Murillo Rubio

Role: primary

Alberto Romero Palacios

Role: primary

Concepción Fernández Roldán

Role: primary

María José García País

Role: primary

Javier Cobo Reinoso

Role: primary

Antonio Blanco García

Role: primary

Jaime Lora-Tamayo Morillo-Velarde

Role: primary

Beatriz Sobrino Díaz

Role: primary

Enrique Nuño Álvarez

Role: primary

Alfonso del Arco Jiménez

Role: primary

Clara Rosso Fernández

Role: primary

955012144

Irene Borreguero Borreguero

Role: backup

955007609

Juan E Corzo Delgado

Role: primary

José Ramón Paño Pardo

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Garrigos C, Rosso-Fernandez CM, Borreguero I, Rodriguez P, Garcia-Albea R, Bravo-Ferrer JM, Rodriguez-Bano J, Del Toro MD; DURATIOM team. Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM): Protocol for a randomized, pragmatic trial. PLoS One. 2023 May 22;18(5):e0286094. doi: 10.1371/journal.pone.0286094. eCollection 2023.

Reference Type DERIVED
PMID: 37216357 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DURATIOM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Local Antibiotics for Breast Implants
NCT04731025 RECRUITING PHASE3